Bill Text: IL HB4352 | 2023-2024 | 103rd General Assembly | Introduced

---

Bill Title: Amends the Illinois Controlled Substances Act. Provides that Xylazine and Clonazolam are to be regulated under the Act as Schedule II controlled substances.

Spectrum: Partisan Bill (Republican 1-0)

Status: (Introduced) 2024-04-05 - Rule 19(a) / Re-referred to Rules Committee [HB4352 Detail]

Download: Illinois-2023-HB4352-Introduced.html

---

103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4352 Introduced , by Rep. Tom Weber SYNOPSIS AS INTRODUCED:
720 ILCS 570/204 from Ch. 56 1/2, par. 1204
720 ILCS 570/206 from Ch. 56 1/2, par. 1206
Amends the Illinois Controlled Substances Act. Provides that Xylazine and Clonazolam are to be regulated under the Act as Schedule II controlled substances.
LRB103 35349 RLC 65413 b
A BILL FOR
HB4352 LRB103 35349 RLC 65413 b
AN ACT concerning criminal law.
Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
Section 5. The Illinois Controlled Substances Act is
amended by changing Sections 204 and 206 as follows:
(720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)
(Text of Section before amendment by P.A. 103-245)
Sec. 204. (a) The controlled substances listed in this
Section are included in Schedule I.
(b) Unless specifically excepted or unless listed in
another schedule, any of the following opiates, including
their isomers, esters, ethers, salts, and salts of isomers,
esters, and ethers, whenever the existence of such isomers,
esters, ethers and salts is possible within the specific
chemical designation:
(1) Acetylmethadol;
(1.1) Acetyl-alpha-methylfentanyl
(N-[1-(1-methyl-2-phenethyl)-
4-piperidinyl]-N-phenylacetamide);
(2) Allylprodine;
(3) Alphacetylmethadol, except
levo-alphacetylmethadol (also known as levo-alpha-
acetylmethadol, levomethadyl acetate, or LAAM);

HB4352 - 2 - LRB103 35349 RLC 65413 b
(4) Alphameprodine;
(5) Alphamethadol;
(6) Alpha-methylfentanyl
(N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
propanilido) piperidine;
(6.1) Alpha-methylthiofentanyl
(N-[1-methyl-2-(2-thienyl)ethyl-
4-piperidinyl]-N-phenylpropanamide);
(7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
(7.1) PEPAP
(1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
(8) Benzethidine;
(9) Betacetylmethadol;
(9.1) Beta-hydroxyfentanyl
(N-[1-(2-hydroxy-2-phenethyl)-
4-piperidinyl]-N-phenylpropanamide);
(10) Betameprodine;
(11) Betamethadol;
(12) Betaprodine;
(13) Clonitazene;
(14) Dextromoramide;
(15) Diampromide;
(16) Diethylthiambutene;
(17) Difenoxin;
(18) Dimenoxadol;

HB4352 - 3 - LRB103 35349 RLC 65413 b
(19) Dimepheptanol;
(20) Dimethylthiambutene;
(21) Dioxaphetylbutyrate;
(22) Dipipanone;
(23) Ethylmethylthiambutene;
(24) Etonitazene;
(25) Etoxeridine;
(26) Furethidine;
(27) Hydroxpethidine;
(28) Ketobemidone;
(29) Levomoramide;
(30) Levophenacylmorphan;
(31) 3-Methylfentanyl
(N-[3-methyl-1-(2-phenylethyl)-
4-piperidyl]-N-phenylpropanamide);
(31.1) 3-Methylthiofentanyl
(N-[(3-methyl-1-(2-thienyl)ethyl-
4-piperidinyl]-N-phenylpropanamide);
(32) Morpheridine;
(33) Noracymethadol;
(34) Norlevorphanol;
(35) Normethadone;
(36) Norpipanone;
(36.1) Para-fluorofentanyl
(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
4-piperidinyl]propanamide);

HB4352 - 4 - LRB103 35349 RLC 65413 b
(37) Phenadoxone;
(38) Phenampromide;
(39) Phenomorphan;
(40) Phenoperidine;
(41) Piritramide;
(42) Proheptazine;
(43) Properidine;
(44) Propiram;
(45) Racemoramide;
(45.1) Thiofentanyl
(N-phenyl-N-[1-(2-thienyl)ethyl-
4-piperidinyl]-propanamide);
(46) Tilidine;
(47) Trimeperidine;
(48) Beta-hydroxy-3-methylfentanyl (other name:
N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
N-phenylpropanamide);
(49) Furanyl fentanyl (FU-F);
(50) Butyryl fentanyl;
(51) Valeryl fentanyl;
(52) Acetyl fentanyl;
(53) Beta-hydroxy-thiofentanyl;
(54) 3,4-dichloro-N-[2-
(dimethylamino)cyclohexyl]-N-
methylbenzamide (U-47700);
(55) 4-chloro-N-[1-[2-

HB4352 - 5 - LRB103 35349 RLC 65413 b
(4-nitrophenyl)ethyl]-2-piperidinylidene]-
benzenesulfonamide (W-18);
(56) 4-chloro-N-[1-(2-phenylethyl)
-2-piperidinylidene]-benzenesulfonamide (W-15);
(57) acrylfentanyl (acryloylfentanyl).
(c) Unless specifically excepted or unless listed in
another schedule, any of the following opium derivatives, its
salts, isomers and salts of isomers, whenever the existence of
such salts, isomers and salts of isomers is possible within
the specific chemical designation:
(1) Acetorphine;
(2) Acetyldihydrocodeine;
(3) Benzylmorphine;
(4) Codeine methylbromide;
(5) Codeine-N-Oxide;
(6) Cyprenorphine;
(7) Desomorphine;
(8) Diacetyldihydromorphine (Dihydroheroin);
(9) Dihydromorphine;
(10) Drotebanol;
(11) Etorphine (except hydrochloride salt);
(12) Heroin;
(13) Hydromorphinol;
(14) Methyldesorphine;
(15) Methyldihydromorphine;
(16) Morphine methylbromide;

HB4352 - 6 - LRB103 35349 RLC 65413 b
(17) Morphine methylsulfonate;
(18) Morphine-N-Oxide;
(19) Myrophine;
(20) Nicocodeine;
(21) Nicomorphine;
(22) Normorphine;
(23) Pholcodine;
(24) Thebacon.
(d) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
hallucinogenic substances, or which contains any of its salts,
isomers and salts of isomers, whenever the existence of such
salts, isomers, and salts of isomers is possible within the
specific chemical designation (for the purposes of this
paragraph only, the term "isomer" includes the optical,
position and geometric isomers):
(1) 3,4-methylenedioxyamphetamine
(alpha-methyl,3,4-methylenedioxyphenethylamine,
methylenedioxyamphetamine, MDA);
(1.1) Alpha-ethyltryptamine
(some trade or other names: etryptamine;
MONASE; alpha-ethyl-1H-indole-3-ethanamine;
3-(2-aminobutyl)indole; a-ET; and AET);
(2) 3,4-methylenedioxymethamphetamine (MDMA);
(2.1) 3,4-methylenedioxy-N-ethylamphetamine

HB4352 - 7 - LRB103 35349 RLC 65413 b
(also known as: N-ethyl-alpha-methyl-
3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
and MDEA);
(2.2) N-Benzylpiperazine (BZP);
(2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
(3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
(4) 3,4,5-trimethoxyamphetamine (TMA);
(5) (Blank);
(6) Diethyltryptamine (DET);
(7) Dimethyltryptamine (DMT);
(7.1) 5-Methoxy-diallyltryptamine;
(8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
(9) Ibogaine (some trade and other names:
7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
indole; Tabernanthe iboga);
(10) Lysergic acid diethylamide;
(10.1) Salvinorin A;
(10.5) Salvia divinorum (meaning all parts of the
plant presently classified botanically as Salvia
divinorum, whether growing or not, the seeds thereof, any
extract from any part of that plant, and every compound,
manufacture, salts, isomers, and salts of isomers whenever
the existence of such salts, isomers, and salts of isomers
is possible within the specific chemical designation,
derivative, mixture, or preparation of that plant, its

HB4352 - 8 - LRB103 35349 RLC 65413 b
seeds or extracts);
(11) 3,4,5-trimethoxyphenethylamine (Mescaline);
(12) Peyote (meaning all parts of the plant presently
classified botanically as Lophophora williamsii Lemaire,
whether growing or not, the seeds thereof, any extract
from any part of that plant, and every compound,
manufacture, salts, derivative, mixture, or preparation of
that plant, its seeds or extracts);
(13) N-ethyl-3-piperidyl benzilate (JB 318);
(14) N-methyl-3-piperidyl benzilate;
(14.1) N-hydroxy-3,4-methylenedioxyamphetamine
(also known as N-hydroxy-alpha-methyl-
3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
(15) Parahexyl; some trade or other names:
3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
dibenzo (b,d) pyran; Synhexyl;
(16) Psilocybin;
(17) Psilocyn;
(18) Alpha-methyltryptamine (AMT);
(19) 2,5-dimethoxyamphetamine
(2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
(20) 4-bromo-2,5-dimethoxyamphetamine
(4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
4-bromo-2,5-DMA);
(20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
Some trade or other names: 2-(4-bromo-

HB4352 - 9 - LRB103 35349 RLC 65413 b
2,5-dimethoxyphenyl)-1-aminoethane;
alpha-desmethyl DOB, 2CB, Nexus;
(21) 4-methoxyamphetamine
(4-methoxy-alpha-methylphenethylamine;
paramethoxyamphetamine; PMA);
(22) (Blank);
(23) Ethylamine analog of phencyclidine.
Some trade or other names:
N-ethyl-1-phenylcyclohexylamine,
(1-phenylcyclohexyl) ethylamine,
N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
(24) Pyrrolidine analog of phencyclidine. Some trade
or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
PHP;
(25) 5-methoxy-3,4-methylenedioxy-amphetamine;
(26) 2,5-dimethoxy-4-ethylamphetamine
(another name: DOET);
(27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
(another name: TCPy);
(28) (Blank);
(29) Thiophene analog of phencyclidine (some trade
or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
2-thienyl analog of phencyclidine; TPCP; TCP);
(29.1) Benzothiophene analog of phencyclidine. Some
trade or other names: BTCP or benocyclidine;
(29.2) 3-Methoxyphencyclidine (3-MeO-PCP);

HB4352 - 10 - LRB103 35349 RLC 65413 b
(30) Bufotenine (some trade or other names:
3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
3-(2-dimethylaminoethyl)-5-indolol;
5-hydroxy-N,N-dimethyltryptamine;
N,N-dimethylserotonin; mappine);
(31) (Blank);
(32) (Blank);
(33) (Blank);
(34) (Blank);
(34.5) (Blank);
(35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
(2-methyloctan-2-yl)-6a,7,
10,10a-tetrahydrobenzo[c]chromen-1-ol
Some trade or other names: HU-210;
(35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-
dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
tetrahydrobenzo[c]chromen-1-ol, its isomers,
salts, and salts of isomers; Some trade or other
names: HU-210, Dexanabinol;
(36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
6,6-dimethyl-3-(2-methyloctan-2-yl)-
6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
Some trade or other names: HU-211;
(37) (Blank);
(38) (Blank);
(39) (Blank);

HB4352 - 11 - LRB103 35349 RLC 65413 b
(40) (Blank);
(41) (Blank);
(42) Any compound structurally derived from
3-(1-naphthoyl)indole or
1H-indol-3-yl-(1-naphthyl)methane by substitution at the
nitrogen atom of the indole ring by alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl whether or not further substituted
in the indole ring to any extent, whether or not
substituted in the naphthyl ring to any extent. Examples
of this structural class include, but are not limited to,
JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
(43) Any compound structurally derived from
3-(1-naphthoyl)pyrrole by substitution at the nitrogen
atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
in the pyrrole ring to any extent, whether or not
substituted in the naphthyl ring to any extent. Examples
of this structural class include, but are not limited to,
JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;
(44) Any compound structurally derived from
1-(1-naphthylmethyl)indene by substitution at the
3-position of the indene ring by alkyl, haloalkyl,

HB4352 - 12 - LRB103 35349 RLC 65413 b
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl whether or not further substituted
in the indene ring to any extent, whether or not
substituted in the naphthyl ring to any extent. Examples
of this structural class include, but are not limited to,
JWH-176;
(45) Any compound structurally derived from
3-phenylacetylindole by substitution at the nitrogen atom
of the indole ring with alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
in the indole ring to any extent, whether or not
substituted in the phenyl ring to any extent. Examples of
this structural class include, but are not limited to,
JWH-167, JWH-250, JWH-251, and RCS-8;
(46) Any compound structurally derived from
2-(3-hydroxycyclohexyl)phenol by substitution at the
5-position of the phenolic ring by alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not substituted in the
cyclohexyl ring to any extent. Examples of this structural
class include, but are not limited to, CP 47, 497 and its
C8 homologue (cannabicyclohexanol);

HB4352 - 13 - LRB103 35349 RLC 65413 b
(46.1) Any compound structurally derived from
3-(benzoyl) indole with substitution at the nitrogen atom
of the indole ring by an alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl group whether or not further
substituted in the indole ring to any extent and whether
or not substituted in the phenyl ring to any extent.
Examples of this structural class include, but are not
limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN
48,098), and RCS-4;
(47) (Blank);
(48) (Blank);
(49) (Blank);
(50) (Blank);
(51) (Blank);
(52) (Blank);
(53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
Some trade or other names: 2C-T-7;
(53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some
trade or other names: 2C-E;
(53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
trade or other names: 2C-D;
(53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
trade or other names: 2C-C;
(53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade

HB4352 - 14 - LRB103 35349 RLC 65413 b
or other names: 2C-I;
(53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
trade or other names: 2C-T-2;
(53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
Some trade or other names: 2C-T-4;
(53.7) 2,5-dimethoxyphenethylamine. Some trade or
other names: 2C-H;
(53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some
trade or other names: 2C-N;
(53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
trade or other names: 2C-P;
(53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.
Some trade or other names: 2C-G;
(53.11) The N-(2-methoxybenzyl) derivative of any 2C
phenethylamine referred to in subparagraphs (20.1), (53),
(53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
(53.8), (53.9), and (53.10) including, but not limited to,
25I-NBOMe and 25C-NBOMe;
(54) 5-Methoxy-N,N-diisopropyltryptamine;
(55) (Blank);
(56) (Blank);
(57) (Blank);
(58) (Blank);
(59) 3-cyclopropoylindole with substitution at the
nitrogen atom of the indole ring by alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,

HB4352 - 15 - LRB103 35349 RLC 65413 b
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indole ring to any extent, whether or not
substituted on the cyclopropyl ring to any extent:
including, but not limited to, XLR11, UR144, FUB-144;
(60) 3-adamantoylindole with substitution at the
nitrogen atom of the indole ring by alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indole ring to any extent, whether or not
substituted on the adamantyl ring to any extent:
including, but not limited to, AB-001;
(61) N-(adamantyl)-indole-3-carboxamide with
substitution at the nitrogen atom of the indole ring by
alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
cycloalkylethyl, aryl halide, alkyl aryl halide,
1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indole ring to any extent, whether or not
substituted on the adamantyl ring to any extent:
including, but not limited to, APICA/2NE-1, STS-135;
(62) N-(adamantyl)-indazole-3-carboxamide with
substitution at a nitrogen atom of the indazole ring by
alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
cycloalkylethyl, aryl halide, alkyl aryl halide,

HB4352 - 16 - LRB103 35349 RLC 65413 b
1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent, whether or not
substituted on the adamantyl ring to any extent:
including, but not limited to, AKB48, 5F-AKB48;
(63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
with substitution at the nitrogen atom of the indole ring
by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
cycloalkylethyl, aryl halide, alkyl aryl halide,
1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indole ring to any extent, whether or not
substituted on the quinoline ring to any extent:
including, but not limited to, PB22, 5F-PB22, FUB-PB-22;
(64) 3-(1-naphthoyl)indazole with substitution at the
nitrogen atom of the indazole ring by alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent, whether or not
substituted on the naphthyl ring to any extent: including,
but not limited to, THJ-018, THJ-2201;
(65) 2-(1-naphthoyl)benzimidazole with substitution
at the nitrogen atom of the benzimidazole ring by alkyl,
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
aryl halide, alkyl aryl halide,

HB4352 - 17 - LRB103 35349 RLC 65413 b
1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the benzimidazole ring to any extent, whether or not
substituted on the naphthyl ring to any extent: including,
but not limited to, FUBIMINA;
(66)
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
3-carboxamide with substitution on the nitrogen atom of
the indazole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;
(67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
indazole-3-carboxamide with substitution on the nitrogen
atom of the indazole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, ADB-PINACA, ADB-FUBINACA;
(68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
indole-3-carboxamide with substitution on the nitrogen
atom of the indole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl

HB4352 - 18 - LRB103 35349 RLC 65413 b
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indole ring to any extent: including, but not
limited to, ADBICA, 5F-ADBICA;
(69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
3-carboxamide with substitution on the nitrogen atom of
the indole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indole ring to any extent: including, but not
limited to, ABICA, 5F-ABICA;
(70) Methyl 2-(1H-indazole-3-carboxamido)-3-
methylbutanoate with substitution on the nitrogen atom of
the indazole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, AMB, 5F-AMB;
(71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
dimethylbutanoate with substitution on the nitrogen atom
of the indazole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted

HB4352 - 19 - LRB103 35349 RLC 65413 b
on the indazole ring to any extent: including, but not
limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;
(72) Methyl 2-(1H-indole-3-carboxamido)-3-
methylbutanoate with substitution on the nitrogen atom of
the indole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, MMB018, MMB2201, and AMB-CHMICA;
(73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
dimethylbutanoate with substitution on the nitrogen atom
of the indole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, MDMB-CHMICA;
(74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
indazole-3-carboxamide with substitution on the nitrogen
atom of the indazole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;

HB4352 - 20 - LRB103 35349 RLC 65413 b
(75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-
3-carboxamide with substitution on the nitrogen atom of
the indole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, APP-PICA and 5-fluoro-APP-PICA;
(76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
4-AcO-DMT;
(77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
name 5-MeO-MIPT;
(78) 4-hydroxy Diethyltryptamine (4-HO-DET);
(79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
(80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
(81) 4-hydroxy-N-methyl-N-isopropyltryptamine
(4-HO-MiPT);
(82) Fluorophenylpiperazine;
(83) Methoxetamine;
(84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
ethcathinone).
(e) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances having a depressant effect on the central nervous
system, including its salts, isomers, and salts of isomers

HB4352 - 21 - LRB103 35349 RLC 65413 b
whenever the existence of such salts, isomers, and salts of
isomers is possible within the specific chemical designation:
(1) mecloqualone;
(2) methaqualone; and
(3) gamma hydroxybutyric acid.
(f) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances having a stimulant effect on the central nervous
system, including its salts, isomers, and salts of isomers:
(1) Fenethylline;
(2) N-ethylamphetamine;
(3) Aminorex (some other names:
2-amino-5-phenyl-2-oxazoline; aminoxaphen;
4-5-dihydro-5-phenyl-2-oxazolamine) and its
salts, optical isomers, and salts of optical isomers;
(4) Methcathinone (some other names:
2-methylamino-1-phenylpropan-1-one;
Ephedrone; 2-(methylamino)-propiophenone;
alpha-(methylamino)propiophenone; N-methylcathinone;
methycathinone; Monomethylpropion; UR 1431) and its
salts, optical isomers, and salts of optical isomers;
(5) Cathinone (some trade or other names:
2-aminopropiophenone; alpha-aminopropiophenone;
2-amino-1-phenyl-propanone; norephedrone);
(6) N,N-dimethylamphetamine (also known as:

HB4352 - 22 - LRB103 35349 RLC 65413 b
N,N-alpha-trimethyl-benzeneethanamine;
N,N-alpha-trimethylphenethylamine);
(7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
(8) 3,4-Methylenedioxypyrovalerone (MDPV);
(9) Halogenated amphetamines and
methamphetamines - any compound derived from either
amphetamine or methamphetamine through the substitution
of a halogen on the phenyl ring, including, but not
limited to, 2-fluoroamphetamine, 3-
fluoroamphetamine and 4-fluoroamphetamine;
(10) Aminopropylbenzofuran (APB):
including 4-(2-Aminopropyl) benzofuran, 5-
(2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
benzofuran, and 7-(2-Aminopropyl) benzofuran;
(11) Aminopropyldihydrobenzofuran (APDB):
including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;
(12) Methylaminopropylbenzofuran
(MAPB): including 4-(2-methylaminopropyl)
benzofuran, 5-(2-methylaminopropyl)benzofuran,
6-(2-methylaminopropyl)benzofuran
and 7-(2-methylaminopropyl)benzofuran.
(g) Temporary listing of substances subject to emergency

HB4352 - 23 - LRB103 35349 RLC 65413 b
scheduling. Any material, compound, mixture, or preparation
that contains any quantity of the following substances:
(1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
(benzylfentanyl), its optical isomers, isomers, salts, and
salts of isomers;
(2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
phenylpropanamide (thenylfentanyl), its optical isomers,
salts, and salts of isomers.
(h) Synthetic cathinones. Unless specifically excepted,
any chemical compound which is not approved by the United
States Food and Drug Administration or, if approved, is not
dispensed or possessed in accordance with State or federal
law, not including bupropion, structurally derived from
2-aminopropan-1-one by substitution at the 1-position with
either phenyl, naphthyl, or thiophene ring systems, whether or
not the compound is further modified in one or more of the
following ways:
(1) by substitution in the ring system to any extent
with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
halide substituents, whether or not further substituted in
the ring system by one or more other univalent
substituents. Examples of this class include, but are not
limited to, 3,4-Methylenedioxycathinone (bk-MDA);
(2) by substitution at the 3-position with an acyclic
alkyl substituent. Examples of this class include, but are
not limited to, 2-methylamino-1-phenylbutan-1-one

HB4352 - 24 - LRB103 35349 RLC 65413 b
(buphedrone); or
(3) by substitution at the 2-amino nitrogen atom with
alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
inclusion of the 2-amino nitrogen atom in a cyclic
structure. Examples of this class include, but are not
limited to, Dimethylcathinone, Ethcathinone, and
a-Pyrrolidinopropiophenone (a-PPP); or
Any other synthetic cathinone which is not approved by the
United States Food and Drug Administration or, if approved, is
not dispensed or possessed in accordance with State or federal
law.
(i) Synthetic cannabinoids or piperazines. Any synthetic
cannabinoid or piperazine which is not approved by the United
States Food and Drug Administration or, if approved, which is
not dispensed or possessed in accordance with State and
federal law.
(Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff.
8-14-18.)
(Text of Section after amendment by P.A. 103-245)
Sec. 204. (a) The controlled substances listed in this
Section are included in Schedule I.
(b) Unless specifically excepted or unless listed in
another schedule, any of the following opiates, including
their isomers, esters, ethers, salts, and salts of isomers,

HB4352 - 25 - LRB103 35349 RLC 65413 b
esters, and ethers, whenever the existence of such isomers,
esters, ethers and salts is possible within the specific
chemical designation:
(1) Acetylmethadol;
(1.1) Acetyl-alpha-methylfentanyl
(N-[1-(1-methyl-2-phenethyl)-
4-piperidinyl]-N-phenylacetamide);
(2) Allylprodine;
(3) Alphacetylmethadol, except
levo-alphacetylmethadol (also known as levo-alpha-
acetylmethadol, levomethadyl acetate, or LAAM);
(4) Alphameprodine;
(5) Alphamethadol;
(6) Alpha-methylfentanyl
(N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
propanilido) piperidine;
(6.1) Alpha-methylthiofentanyl
(N-[1-methyl-2-(2-thienyl)ethyl-
4-piperidinyl]-N-phenylpropanamide);
(7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
(7.1) PEPAP
(1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
(8) Benzethidine;
(9) Betacetylmethadol;
(9.1) Beta-hydroxyfentanyl

HB4352 - 26 - LRB103 35349 RLC 65413 b
(N-[1-(2-hydroxy-2-phenethyl)-
4-piperidinyl]-N-phenylpropanamide);
(10) Betameprodine;
(11) Betamethadol;
(12) Betaprodine;
(13) Clonitazene;
(14) Dextromoramide;
(15) Diampromide;
(16) Diethylthiambutene;
(17) Difenoxin;
(18) Dimenoxadol;
(19) Dimepheptanol;
(20) Dimethylthiambutene;
(21) Dioxaphetylbutyrate;
(22) Dipipanone;
(23) Ethylmethylthiambutene;
(24) Etonitazene;
(25) Etoxeridine;
(26) Furethidine;
(27) Hydroxpethidine;
(28) Ketobemidone;
(29) Levomoramide;
(30) Levophenacylmorphan;
(31) 3-Methylfentanyl
(N-[3-methyl-1-(2-phenylethyl)-
4-piperidyl]-N-phenylpropanamide);

HB4352 - 27 - LRB103 35349 RLC 65413 b
(31.1) 3-Methylthiofentanyl
(N-[(3-methyl-1-(2-thienyl)ethyl-
4-piperidinyl]-N-phenylpropanamide);
(32) Morpheridine;
(33) Noracymethadol;
(34) Norlevorphanol;
(35) Normethadone;
(36) Norpipanone;
(36.1) Para-fluorofentanyl
(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
4-piperidinyl]propanamide);
(37) Phenadoxone;
(38) Phenampromide;
(39) Phenomorphan;
(40) Phenoperidine;
(41) Piritramide;
(42) Proheptazine;
(43) Properidine;
(44) Propiram;
(45) Racemoramide;
(45.1) Thiofentanyl
(N-phenyl-N-[1-(2-thienyl)ethyl-
4-piperidinyl]-propanamide);
(46) Tilidine;
(47) Trimeperidine;
(48) Beta-hydroxy-3-methylfentanyl (other name:

HB4352 - 28 - LRB103 35349 RLC 65413 b
N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
N-phenylpropanamide);
(49) Furanyl fentanyl (FU-F);
(50) Butyryl fentanyl;
(51) Valeryl fentanyl;
(52) Acetyl fentanyl;
(53) Beta-hydroxy-thiofentanyl;
(54) 3,4-dichloro-N-[2-
(dimethylamino)cyclohexyl]-N-
methylbenzamide (U-47700);
(55) 4-chloro-N-[1-[2-
(4-nitrophenyl)ethyl]-2-piperidinylidene]-
benzenesulfonamide (W-18);
(56) 4-chloro-N-[1-(2-phenylethyl)
-2-piperidinylidene]-benzenesulfonamide (W-15);
(57) acrylfentanyl (acryloylfentanyl).
(c) Unless specifically excepted or unless listed in
another schedule, any of the following opium derivatives, its
salts, isomers and salts of isomers, whenever the existence of
such salts, isomers and salts of isomers is possible within
the specific chemical designation:
(1) Acetorphine;
(2) Acetyldihydrocodeine;
(3) Benzylmorphine;
(4) Codeine methylbromide;
(5) Codeine-N-Oxide;

HB4352 - 29 - LRB103 35349 RLC 65413 b
(6) Cyprenorphine;
(7) Desomorphine;
(8) Diacetyldihydromorphine (Dihydroheroin);
(9) Dihydromorphine;
(10) Drotebanol;
(11) Etorphine (except hydrochloride salt);
(12) Heroin;
(13) Hydromorphinol;
(14) Methyldesorphine;
(15) Methyldihydromorphine;
(16) Morphine methylbromide;
(17) Morphine methylsulfonate;
(18) Morphine-N-Oxide;
(19) Myrophine;
(20) Nicocodeine;
(21) Nicomorphine;
(22) Normorphine;
(23) Pholcodine;
(24) Thebacon.
(d) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
hallucinogenic substances, or which contains any of its salts,
isomers and salts of isomers, whenever the existence of such
salts, isomers, and salts of isomers is possible within the
specific chemical designation (for the purposes of this

HB4352 - 30 - LRB103 35349 RLC 65413 b
paragraph only, the term "isomer" includes the optical,
position and geometric isomers):
(1) 3,4-methylenedioxyamphetamine
(alpha-methyl,3,4-methylenedioxyphenethylamine,
methylenedioxyamphetamine, MDA);
(1.1) Alpha-ethyltryptamine
(some trade or other names: etryptamine;
MONASE; alpha-ethyl-1H-indole-3-ethanamine;
3-(2-aminobutyl)indole; a-ET; and AET);
(2) 3,4-methylenedioxymethamphetamine (MDMA);
(2.1) 3,4-methylenedioxy-N-ethylamphetamine
(also known as: N-ethyl-alpha-methyl-
3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
and MDEA);
(2.2) N-Benzylpiperazine (BZP);
(2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
(3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
(4) 3,4,5-trimethoxyamphetamine (TMA);
(5) (Blank);
(6) Diethyltryptamine (DET);
(7) Dimethyltryptamine (DMT);
(7.1) 5-Methoxy-diallyltryptamine;
(8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
(9) Ibogaine (some trade and other names:
7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]

HB4352 - 31 - LRB103 35349 RLC 65413 b
indole; Tabernanthe iboga);
(10) Lysergic acid diethylamide;
(10.1) Salvinorin A;
(10.5) Salvia divinorum (meaning all parts of the
plant presently classified botanically as Salvia
divinorum, whether growing or not, the seeds thereof, any
extract from any part of that plant, and every compound,
manufacture, salts, isomers, and salts of isomers whenever
the existence of such salts, isomers, and salts of isomers
is possible within the specific chemical designation,
derivative, mixture, or preparation of that plant, its
seeds or extracts);
(11) 3,4,5-trimethoxyphenethylamine (Mescaline);
(12) Peyote (meaning all parts of the plant presently
classified botanically as Lophophora williamsii Lemaire,
whether growing or not, the seeds thereof, any extract
from any part of that plant, and every compound,
manufacture, salts, derivative, mixture, or preparation of
that plant, its seeds or extracts);
(13) N-ethyl-3-piperidyl benzilate (JB 318);
(14) N-methyl-3-piperidyl benzilate;
(14.1) N-hydroxy-3,4-methylenedioxyamphetamine
(also known as N-hydroxy-alpha-methyl-
3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
(15) Parahexyl; some trade or other names:
3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-

HB4352 - 32 - LRB103 35349 RLC 65413 b
dibenzo (b,d) pyran; Synhexyl;
(16) Psilocybin;
(17) Psilocyn;
(18) Alpha-methyltryptamine (AMT);
(19) 2,5-dimethoxyamphetamine
(2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
(20) 4-bromo-2,5-dimethoxyamphetamine
(4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
4-bromo-2,5-DMA);
(20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
Some trade or other names: 2-(4-bromo-
2,5-dimethoxyphenyl)-1-aminoethane;
alpha-desmethyl DOB, 2CB, Nexus;
(21) 4-methoxyamphetamine
(4-methoxy-alpha-methylphenethylamine;
paramethoxyamphetamine; PMA);
(22) (Blank);
(23) Ethylamine analog of phencyclidine.
Some trade or other names:
N-ethyl-1-phenylcyclohexylamine,
(1-phenylcyclohexyl) ethylamine,
N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
(24) Pyrrolidine analog of phencyclidine. Some trade
or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
PHP;
(25) 5-methoxy-3,4-methylenedioxy-amphetamine;

HB4352 - 33 - LRB103 35349 RLC 65413 b
(26) 2,5-dimethoxy-4-ethylamphetamine
(another name: DOET);
(27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
(another name: TCPy);
(28) (Blank);
(29) Thiophene analog of phencyclidine (some trade
or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
2-thienyl analog of phencyclidine; TPCP; TCP);
(29.1) Benzothiophene analog of phencyclidine. Some
trade or other names: BTCP or benocyclidine;
(29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
(30) Bufotenine (some trade or other names:
3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
3-(2-dimethylaminoethyl)-5-indolol;
5-hydroxy-N,N-dimethyltryptamine;
N,N-dimethylserotonin; mappine);
(31) (Blank);
(32) (Blank);
(33) (Blank);
(34) (Blank);
(34.5) (Blank);
(35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
(2-methyloctan-2-yl)-6a,7,
10,10a-tetrahydrobenzo[c]chromen-1-ol
Some trade or other names: HU-210;
(35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-

HB4352 - 34 - LRB103 35349 RLC 65413 b
dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
tetrahydrobenzo[c]chromen-1-ol, its isomers,
salts, and salts of isomers; Some trade or other
names: HU-210, Dexanabinol;
(36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
6,6-dimethyl-3-(2-methyloctan-2-yl)-
6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
Some trade or other names: HU-211;
(37) (Blank);
(38) (Blank);
(39) (Blank);
(40) (Blank);
(41) (Blank);
(42) Any compound structurally derived from
3-(1-naphthoyl)indole or
1H-indol-3-yl-(1-naphthyl)methane by substitution at the
nitrogen atom of the indole ring by alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl whether or not further substituted
in the indole ring to any extent, whether or not
substituted in the naphthyl ring to any extent. Examples
of this structural class include, but are not limited to,
JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
(43) Any compound structurally derived from
3-(1-naphthoyl)pyrrole by substitution at the nitrogen

HB4352 - 35 - LRB103 35349 RLC 65413 b
atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
in the pyrrole ring to any extent, whether or not
substituted in the naphthyl ring to any extent. Examples
of this structural class include, but are not limited to,
JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;
(44) Any compound structurally derived from
1-(1-naphthylmethyl)indene by substitution at the
3-position of the indene ring by alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl whether or not further substituted
in the indene ring to any extent, whether or not
substituted in the naphthyl ring to any extent. Examples
of this structural class include, but are not limited to,
JWH-176;
(45) Any compound structurally derived from
3-phenylacetylindole by substitution at the nitrogen atom
of the indole ring with alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
in the indole ring to any extent, whether or not
substituted in the phenyl ring to any extent. Examples of

HB4352 - 36 - LRB103 35349 RLC 65413 b
this structural class include, but are not limited to,
JWH-167, JWH-250, JWH-251, and RCS-8;
(46) Any compound structurally derived from
2-(3-hydroxycyclohexyl)phenol by substitution at the
5-position of the phenolic ring by alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not substituted in the
cyclohexyl ring to any extent. Examples of this structural
class include, but are not limited to, CP 47, 497 and its
C8 homologue (cannabicyclohexanol);
(46.1) Any compound structurally derived from
3-(benzoyl) indole with substitution at the nitrogen atom
of the indole ring by an alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl group whether or not further
substituted in the indole ring to any extent and whether
or not substituted in the phenyl ring to any extent.
Examples of this structural class include, but are not
limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN
48,098), and RCS-4;
(47) (Blank);
(48) (Blank);
(49) (Blank);
(50) (Blank);

HB4352 - 37 - LRB103 35349 RLC 65413 b
(51) (Blank);
(52) (Blank);
(53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
Some trade or other names: 2C-T-7;
(53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some
trade or other names: 2C-E;
(53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
trade or other names: 2C-D;
(53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
trade or other names: 2C-C;
(53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
or other names: 2C-I;
(53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
trade or other names: 2C-T-2;
(53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
Some trade or other names: 2C-T-4;
(53.7) 2,5-dimethoxyphenethylamine. Some trade or
other names: 2C-H;
(53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some
trade or other names: 2C-N;
(53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
trade or other names: 2C-P;
(53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.
Some trade or other names: 2C-G;
(53.11) The N-(2-methoxybenzyl) derivative of any 2C
phenethylamine referred to in subparagraphs (20.1), (53),

HB4352 - 38 - LRB103 35349 RLC 65413 b
(53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
(53.8), (53.9), and (53.10) including, but not limited to,
25I-NBOMe and 25C-NBOMe;
(54) 5-Methoxy-N,N-diisopropyltryptamine;
(55) (Blank);
(56) (Blank);
(57) (Blank);
(58) (Blank);
(59) 3-cyclopropoylindole with substitution at the
nitrogen atom of the indole ring by alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indole ring to any extent, whether or not
substituted on the cyclopropyl ring to any extent:
including, but not limited to, XLR11, UR144, FUB-144;
(60) 3-adamantoylindole with substitution at the
nitrogen atom of the indole ring by alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indole ring to any extent, whether or not
substituted on the adamantyl ring to any extent:
including, but not limited to, AB-001;
(61) N-(adamantyl)-indole-3-carboxamide with
substitution at the nitrogen atom of the indole ring by

HB4352 - 39 - LRB103 35349 RLC 65413 b
alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
cycloalkylethyl, aryl halide, alkyl aryl halide,
1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indole ring to any extent, whether or not
substituted on the adamantyl ring to any extent:
including, but not limited to, APICA/2NE-1, STS-135;
(62) N-(adamantyl)-indazole-3-carboxamide with
substitution at a nitrogen atom of the indazole ring by
alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
cycloalkylethyl, aryl halide, alkyl aryl halide,
1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent, whether or not
substituted on the adamantyl ring to any extent:
including, but not limited to, AKB48, 5F-AKB48;
(63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
with substitution at the nitrogen atom of the indole ring
by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
cycloalkylethyl, aryl halide, alkyl aryl halide,
1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indole ring to any extent, whether or not
substituted on the quinoline ring to any extent:
including, but not limited to, PB22, 5F-PB22, FUB-PB-22;
(64) 3-(1-naphthoyl)indazole with substitution at the

HB4352 - 40 - LRB103 35349 RLC 65413 b
nitrogen atom of the indazole ring by alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent, whether or not
substituted on the naphthyl ring to any extent: including,
but not limited to, THJ-018, THJ-2201;
(65) 2-(1-naphthoyl)benzimidazole with substitution
at the nitrogen atom of the benzimidazole ring by alkyl,
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
aryl halide, alkyl aryl halide,
1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the benzimidazole ring to any extent, whether or not
substituted on the naphthyl ring to any extent: including,
but not limited to, FUBIMINA;
(66)
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
3-carboxamide with substitution on the nitrogen atom of
the indazole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;
(67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-

HB4352 - 41 - LRB103 35349 RLC 65413 b
indazole-3-carboxamide with substitution on the nitrogen
atom of the indazole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, ADB-PINACA, ADB-FUBINACA;
(68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
indole-3-carboxamide with substitution on the nitrogen
atom of the indole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indole ring to any extent: including, but not
limited to, ADBICA, 5F-ADBICA;
(69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
3-carboxamide with substitution on the nitrogen atom of
the indole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indole ring to any extent: including, but not
limited to, ABICA, 5F-ABICA;
(70) Methyl 2-(1H-indazole-3-carboxamido)-3-
methylbutanoate with substitution on the nitrogen atom of
the indazole ring by alkyl, haloalkyl, alkenyl,

HB4352 - 42 - LRB103 35349 RLC 65413 b
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, AMB, 5F-AMB;
(71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
dimethylbutanoate with substitution on the nitrogen atom
of the indazole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;
(72) Methyl 2-(1H-indole-3-carboxamido)-3-
methylbutanoate with substitution on the nitrogen atom of
the indole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, MMB018, MMB2201, and AMB-CHMICA;
(73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
dimethylbutanoate with substitution on the nitrogen atom
of the indole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or

HB4352 - 43 - LRB103 35349 RLC 65413 b
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, MDMB-CHMICA;
(74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
indazole-3-carboxamide with substitution on the nitrogen
atom of the indazole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;
(75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-
3-carboxamide with substitution on the nitrogen atom of
the indole ring by alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
halide, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl, whether or not further substituted
on the indazole ring to any extent: including, but not
limited to, APP-PICA and 5-fluoro-APP-PICA;
(76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
4-AcO-DMT;
(77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
name 5-MeO-MIPT;
(78) 4-hydroxy Diethyltryptamine (4-HO-DET);
(79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
(80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);

HB4352 - 44 - LRB103 35349 RLC 65413 b
(81) 4-hydroxy-N-methyl-N-isopropyltryptamine
(4-HO-MiPT);
(82) Fluorophenylpiperazine;
(83) Methoxetamine;
(84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
ethcathinone).
(e) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances having a depressant effect on the central nervous
system, including its salts, isomers, and salts of isomers
whenever the existence of such salts, isomers, and salts of
isomers is possible within the specific chemical designation:
(1) mecloqualone;
(2) methaqualone; and
(3) gamma hydroxybutyric acid.
(f) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances having a stimulant effect on the central nervous
system, including its salts, isomers, and salts of isomers:
(1) Fenethylline;
(2) N-ethylamphetamine;
(3) Aminorex (some other names:
2-amino-5-phenyl-2-oxazoline; aminoxaphen;
4-5-dihydro-5-phenyl-2-oxazolamine) and its

HB4352 - 45 - LRB103 35349 RLC 65413 b
salts, optical isomers, and salts of optical isomers;
(4) Methcathinone (some other names:
2-methylamino-1-phenylpropan-1-one;
Ephedrone; 2-(methylamino)-propiophenone;
alpha-(methylamino)propiophenone; N-methylcathinone;
methycathinone; Monomethylpropion; UR 1431) and its
salts, optical isomers, and salts of optical isomers;
(5) Cathinone (some trade or other names:
2-aminopropiophenone; alpha-aminopropiophenone;
2-amino-1-phenyl-propanone; norephedrone);
(6) N,N-dimethylamphetamine (also known as:
N,N-alpha-trimethyl-benzeneethanamine;
N,N-alpha-trimethylphenethylamine);
(7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
(8) 3,4-Methylenedioxypyrovalerone (MDPV);
(9) Halogenated amphetamines and
methamphetamines - any compound derived from either
amphetamine or methamphetamine through the substitution
of a halogen on the phenyl ring, including, but not
limited to, 2-fluoroamphetamine, 3-
fluoroamphetamine and 4-fluoroamphetamine;
(10) Aminopropylbenzofuran (APB):
including 4-(2-Aminopropyl) benzofuran, 5-
(2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
benzofuran, and 7-(2-Aminopropyl) benzofuran;

HB4352 - 46 - LRB103 35349 RLC 65413 b
(11) Aminopropyldihydrobenzofuran (APDB):
including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;
(12) Methylaminopropylbenzofuran
(MAPB): including 4-(2-methylaminopropyl)
benzofuran, 5-(2-methylaminopropyl)benzofuran,
6-(2-methylaminopropyl)benzofuran
and 7-(2-methylaminopropyl)benzofuran.
(g) Temporary listing of substances subject to emergency
scheduling. Any material, compound, mixture, or preparation
that contains any quantity of the following substances:
(1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
(benzylfentanyl), its optical isomers, isomers, salts, and
salts of isomers;
(2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
phenylpropanamide (thenylfentanyl), its optical isomers,
salts, and salts of isomers.
(h) Synthetic cathinones. Unless specifically excepted,
any chemical compound which is not approved by the United
States Food and Drug Administration or, if approved, is not
dispensed or possessed in accordance with State or federal
law, not including bupropion, structurally derived from
2-aminopropan-1-one by substitution at the 1-position with
either phenyl, naphthyl, or thiophene ring systems, whether or

HB4352 - 47 - LRB103 35349 RLC 65413 b
not the compound is further modified in one or more of the
following ways:
(1) by substitution in the ring system to any extent
with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
halide substituents, whether or not further substituted in
the ring system by one or more other univalent
substituents. Examples of this class include, but are not
limited to, 3,4-Methylenedioxycathinone (bk-MDA);
(2) by substitution at the 3-position with an acyclic
alkyl substituent. Examples of this class include, but are
not limited to, 2-methylamino-1-phenylbutan-1-one
(buphedrone); or
(3) by substitution at the 2-amino nitrogen atom with
alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
inclusion of the 2-amino nitrogen atom in a cyclic
structure. Examples of this class include, but are not
limited to, Dimethylcathinone, Ethcathinone, and
a-Pyrrolidinopropiophenone (a-PPP); or
Any other synthetic cathinone which is not approved by the
United States Food and Drug Administration or, if approved, is
not dispensed or possessed in accordance with State or federal
law.
(i) Synthetic cannabinoids or piperazines. Any synthetic
cannabinoid or piperazine which is not approved by the United
States Food and Drug Administration or, if approved, which is
not dispensed or possessed in accordance with State and

HB4352 - 48 - LRB103 35349 RLC 65413 b
federal law.
(j) Unless specifically excepted or listed in another
schedule, any chemical compound which is not approved by the
United States Food and Drug Administration or, if approved, is
not dispensed or possessed in accordance with State or federal
law, and is derived from the following structural classes and
their salts:
(1) Benzodiazepine class: A fused 1,4-diazepine and
benzene ring structure with a phenyl connected to the
1,4-diazepine ring, with any substitution(s) or
replacement(s) on the 1,4-diazepine or benzene ring, any
substitution(s) on the phenyl ring, or any combination
thereof. Examples of this class include but are not
limited to: Clonazolam, Flualprazolam; or
(2) Thienodiazepine class: A fused 1,4-diazepine and
thiophene ring structure with a phenyl connected to the
1,4-diazepine ring, with any substitution(s) or
replacement(s) on the 1,4-diazepine or thiophene ring, any
substitution(s) on the phenyl ring, or any combination
thereof. Examples of this class include but are not
limited to: Etizolam.
(Source: P.A. 103-245, eff. 1-1-24.)
(720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)
Sec. 206. (a) The controlled substances listed in this
Section are included in Schedule II.

HB4352 - 49 - LRB103 35349 RLC 65413 b
(b) Unless specifically excepted or unless listed in
another schedule, any of the following substances whether
produced directly or indirectly by extraction from substances
of vegetable origin, or independently by means of chemical
synthesis, or by combination of extraction and chemical
synthesis:
(1) Opium and opiates, and any salt, compound,
derivative or preparation of opium or opiate, excluding
apomorphine, dextrorphan, levopropoxyphene, nalbuphine,
nalmefene, naloxone, and naltrexone, and their respective
salts, but including the following:
(i) Raw Opium;
(ii) Opium extracts;
(iii) Opium fluid extracts;
(iv) Powdered opium;
(v) Granulated opium;
(vi) Tincture of opium;
(vii) Codeine;
(viii) Ethylmorphine;
(ix) Etorphine Hydrochloride;
(x) Hydrocodone;
(xi) Hydromorphone;
(xii) Metopon;
(xiii) Morphine;
(xiii.5) 6-Monoacetylmorphine;
(xiv) Oxycodone;

HB4352 - 50 - LRB103 35349 RLC 65413 b
(xv) Oxymorphone;
(xv.5) Tapentadol;
(xvi) Thebaine;
(xvii) Thebaine-derived butorphanol.
(xviii) Methorphan, except drug products
containing dextromethorphan that may be dispensed
pursuant to a prescription order of a practitioner and
are sold in compliance with the safety and labeling
standards as set forth by the United States Food and
Drug Administration, or drug products containing
dextromethorphan that are sold in solid, tablet,
liquid, capsule, powder, thin film, or gel form and
which are formulated, packaged, and sold in dosages
and concentrations for use as an over-the-counter drug
product. For the purposes of this Section,
"over-the-counter drug product" means a drug that is
available to consumers without a prescription and sold
in compliance with the safety and labeling standards
as set forth by the United States Food and Drug
Administration.
(2) Any salt, compound, isomer, derivative or
preparation thereof which is chemically equivalent or
identical with any of the substances referred to in
subparagraph (1), but not including the isoquinoline
alkaloids of opium;
(3) Opium poppy and poppy straw;

HB4352 - 51 - LRB103 35349 RLC 65413 b
(4) Coca leaves and any salt, compound, isomer, salt
of an isomer, derivative, or preparation of coca leaves
including cocaine or ecgonine, and any salt, compound,
isomer, derivative, or preparation thereof which is
chemically equivalent or identical with any of these
substances, but not including decocainized coca leaves or
extractions of coca leaves which do not contain cocaine or
ecgonine (for the purpose of this paragraph, the term
"isomer" includes optical, positional and geometric
isomers);
(5) Concentrate of poppy straw (the crude extract of
poppy straw in either liquid, solid or powder form which
contains the phenanthrine alkaloids of the opium poppy).
(c) Unless specifically excepted or unless listed in
another schedule any of the following opiates, including their
isomers, esters, ethers, salts, and salts of isomers, whenever
the existence of these isomers, esters, ethers and salts is
possible within the specific chemical designation, dextrorphan
excepted:
(1) Alfentanil;
(1.1) Carfentanil;
(1.2) Thiafentanyl;
(2) Alphaprodine;
(3) Anileridine;
(4) Bezitramide;
(5) Bulk Dextropropoxyphene (non-dosage forms);

HB4352 - 52 - LRB103 35349 RLC 65413 b
(6) Dihydrocodeine;
(7) Diphenoxylate;
(8) Fentanyl;
(9) Sufentanil;
(9.5) Remifentanil;
(10) Isomethadone;
(11) (Blank);
(12) Levorphanol (Levorphan);
(13) Metazocine;
(14) Methadone;
(15) Methadone-Intermediate,
4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
(16) Moramide-Intermediate,
2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
acid;
(17) Pethidine (meperidine);
(18) Pethidine-Intermediate-A,
4-cyano-1-methyl-4-phenylpiperidine;
(19) Pethidine-Intermediate-B,
ethyl-4-phenylpiperidine-4-carboxylate;
(20) Pethidine-Intermediate-C,
1-methyl-4-phenylpiperidine-4-carboxylic acid;
(21) Phenazocine;
(22) Piminodine;
(23) Racemethorphan;
(24) (Blank);

HB4352 - 53 - LRB103 35349 RLC 65413 b
(25) Levo-alphacetylmethadol (some other names:
levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).
(d) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances having a stimulant effect on the central nervous
system:
(1) Amphetamine, its salts, optical isomers, and salts
of its optical isomers;
(2) Methamphetamine, its salts, isomers, and salts of
its isomers;
(3) Phenmetrazine and its salts;
(4) Methylphenidate;
(5) Lisdexamfetamine.
(e) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances having a depressant effect on the central nervous
system, including its salts, isomers, and salts of isomers
whenever the existence of such salts, isomers, and salts of
isomers is possible within the specific chemical designation:
(1) Amobarbital;
(2) Secobarbital;
(3) Pentobarbital;
(4) Pentazocine;
(5) Phencyclidine;

HB4352 - 54 - LRB103 35349 RLC 65413 b
(6) Gluthethimide;
(7) (Blank).
(f) Unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following
substances:
(1) Immediate precursor to amphetamine and
methamphetamine:
(i) Phenylacetone
Some trade or other names: phenyl-2-propanone;
P2P; benzyl methyl ketone; methyl benzyl ketone.
(2) Immediate precursors to phencyclidine:
(i) 1-phenylcyclohexylamine;
(ii) 1-piperidinocyclohexanecarbonitrile (PCC).
(3) Nabilone.
(4) Xylazine: N-(2,6-dimethylpheny1)-5,6-dihydro-
4H-1,3-thiazin-2-amine), including its isomers, esters,
ethers, salts, and salts of isomers, esters, and ethers,
whenever the existence of such isomers, esters, ethers,
and salts is possible within the specific chemical
designation as a Schedule II controlled substance.
(g) Clonazolam.
(Source: P.A. 100-368, eff. 1-1-18.)
Section 95. No acceleration or delay. Where this Act makes
changes in a statute that is represented in this Act by text

HB4352 - 55 - LRB103 35349 RLC 65413 b